$ATTO

Attovia Therapeutics, Inc.

CIK:0002058707|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues [Abstract]
Total revenue	$ 450	$ 0	$ 450	$ 0
Operating Expenses [Abstract]
Research and development (including related party amounts of $178 and $34 for the three months ended June 30, 2026 and 2025, respectively, and $238 and $41 for the six months ended June 30, 2026 and 2025, respectively)	18,946	13,588	35,692	25,444
General and administrative (including related party amounts of $0 for the three months ended June 30, 2026 and 2025, and $0 and $239 for the six months ended June 30, 2026 and 2025, respectively)	3,307	3,032	6,516	7,280
Total operating expenses	22,253	16,620	42,208	32,724
Loss from operations	(21,803)	(16,620)	(41,758)	(32,724)
Other income (expense):
Interest income	1,141	2,041	2,467	3,167
Change in fair value of preferred stock tranche liability	0	0	0	(170)
Other income (expense), net	(25)	140	(52)	137
Total other income (expense), net	1,116	2,181	2,415	3,134
Net loss	(20,687)	(14,439)	(39,343)	(29,590)
Less: Accretion of redeemable convertible preferred stock to its redemption value	0	0	0	(271)
Net loss attributable to common stockholders	$ (20,687)	$ (14,439)	$ (39,343)	$ (29,861)
Net loss per share attributable to common stockholders, - basic	$ (4.88)	$ (3.71)	$ (9.38)	$ (7.75)
Net loss per share attributable to common stockholders, - diluted	$ (4.88)	$ (3.71)	$ (9.38)	$ (7.75)
Weighted-average common shares outstanding, basic	4,237,597	3,895,037	4,195,615	3,851,124
Weighted-average common shares outstanding, diluted	4,237,597	3,895,037	4,195,615	3,851,124
Other comprehensive loss:
Unrealized loss on available-for-sale marketable securities, net	$ (52)	$ (52)	$ (178)	$ (76)
Net loss and other comprehensive loss	(20,739)	(14,491)	(39,521)	(29,666)
Collaboration Revenue [Member]
Revenues [Abstract]
Total revenue	$ 450	$ 0	$ 450	$ 0

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net Income (Loss)	$ (39,343)	$ (29,590)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	1,378	1,025
Depreciation expense	488	350
Net accretion of discounts on marketable securities	(346)	(1,238)
Non-cash lease expense	795	632
Change in fair value of preferred stock tranche liability	0	170
Loss on disposal of property and equipment	0	6
Write-off of deferred offering costs	0	393
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	972	1,106
Accounts payable	3,159	2,174
Accrued and other current liabilities	(1,124)	(1,335)
Operating lease liability	(936)	(175)
Other non-current assets	25	(215)
Net cash used in operating activities	(34,932)	(26,697)
Cash flows from investing activities
Maturities of marketable securities	77,900	37,250
Purchases of marketable securities	(48,174)	(138,823)
Purchases of property and equipment	(361)	(1,886)
Net cash provided by (used in) investing activities	29,365	(103,459)
Cash flows from financing activities
Proceeds from issuance of common stock upon exercise of stock options	42	143
Payments of deferred offering costs	(1,839)	(371)
Net cash (used in) provided by financing activities	(1,797)	141,966
Net change in cash, cash equivalents and restricted cash	(7,364)	11,810
Cash, cash equivalents and restricted cash at the beginning of the period	40,597	31,239
Cash, cash equivalents and restricted cash at the end of the period	33,233	43,049
Supplemental disclosures of noncash investing and financing activities
Deferred offering costs in accounts payable and accrued and other current liabilities	709	4
Vesting of early exercised stock options	78	67
Property and equipment purchases in accounts payable	6	183
Accretion of redeemable convertible preferred stock to its redemption value	0	271
Right-of-use asset obtained in exchange for operating lease liability	0	5,771
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	32,829	42,645
Restricted cash	404	404
Total cash, cash equivalents and restricted cash	33,233	43,049
Series B
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs	0	52,465
Supplemental disclosures of noncash investing and financing activities
Settlement of preferred stock tranche liability upon issuance of Series B redeemable convertible preferred stock	0	6,808
Series C
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs	$ 0	$ 89,729

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 32,829	$ 40,193
Marketable securities	82,303	112,075
Prepaid expenses and other current assets	3,269	4,027
Total current assets	118,401	156,295
Restricted cash	404	404
Property and equipment, net	3,343	3,492
Operating lease right-of-use asset, net	3,578	4,373
Other non-current assets	2,622	1,329
Total assets	128,348	165,893
Current liabilities:
Accounts payable (including related party amounts of $32 and $39 at June, 2026 and December 31, 2025, respectively)	6,002	3,551
Accrued expenses and other current liabilities	4,575	5,535
Operating lease liability, current portion	2,038	1,921
Total current liabilities	12,615	11,007
Operating lease liability, net of current portion	2,288	3,341
Other non-current liabilities	678	755
Total liabilities	15,581	15,103
Commitments and contingencies (Note 6)
Stockholders' deficit:
Common stock - $0.0001 par value; 284,023,000 shares authorized at June 30, 2026 and December 31, 2025; 4,529,100 and 4,507,108 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	1	1
Additional paid-in capital	4,972	3,474
Accumulated other comprehensive (loss) income	(79)	99
Accumulated deficit	(150,353)	(111,010)
Total stockholders' deficit	(145,459)	(107,436)
Total liabilities, redeemable convertible preferred stock, and stockholders' deficit	128,348	165,893
Redeemable Convertible Preferred Stock [Member]
Current liabilities:
Redeemable convertible preferred stock - $0.0001 par value; 199,902,270 shares authorized, issued and outstanding at June 30, 2026 and December 31, 2025; aggregate liquidation preference of $255,850 at June 30, 2026 and December 31, 2025	$ 258,226	$ 258,226